HC Wainwright & Co. Reiterates Buy on Karuna Therapeutics, Maintains $300 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a $300 price target.
August 04, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Karuna Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $300.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Karuna Therapeutics. This could potentially attract more investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100